Obalon Therapeutics, Inc. (OBLN): Price and Financial Metrics


Obalon Therapeutics, Inc. (OBLN): $3.05

-0.19 (-5.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OBLN POWR Grades


  • Growth is the dimension where OBLN ranks best; there it ranks ahead of 72.72% of US stocks.
  • The strongest trend for OBLN is in Value, which has been heading down over the past 31 weeks.
  • OBLN's current lowest rank is in the Quality metric (where it is better than 1.42% of US stocks).

OBLN Stock Summary

  • With a market capitalization of $30,565,782, Obalon Therapeutics Inc has a greater market value than only 5% of US stocks.
  • As for revenue growth, note that OBLN's revenue has grown -64.65% over the past 12 months; that beats the revenue growth of only 4.22% of US companies in our set.
  • In terms of volatility of its share price, OBLN is more volatile than 96.8% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Obalon Therapeutics Inc are NBRV, SNOA, CEI, FTK, and NBY.
  • OBLN's SEC filings can be seen here. And to visit Obalon Therapeutics Inc's official web site, go to www.obalon.com.

OBLN Price Target

For more insight on analysts targets of OBLN, see our OBLN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.15 Average Broker Recommendation 1.5 (Moderate Buy)

OBLN Stock Price Chart Interactive Chart >

Price chart for OBLN

OBLN Price/Volume Stats

Current price $3.05 52-week high $10.77
Prev. close $3.24 52-week low $0.66
Day low $2.95 Volume 26,781,700
Day high $4.80 Avg. volume 7,677,330
50-day MA $2.88 Dividend yield N/A
200-day MA $2.30 Market Cap 30.57M

Obalon Therapeutics, Inc. (OBLN) Company Bio


Obalon Therapeutics, a commercial-stage medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. The company was founded in 2008 and is based in Carlsbad, California.


OBLN Latest News Stream


Event/Time News Detail
Loading, please wait...

OBLN Latest Social Stream


Loading social stream, please wait...

View Full OBLN Social Stream

Latest OBLN News From Around the Web

Below are the latest news stories about Obalon Therapeutics Inc that investors may wish to consider to help them evaluate OBLN as an investment opportunity.

Hedge Funds Are Betting On Obalon Therapeutics, Inc. (OBLN)

No summary available.

Insider Monkey | June 14, 2021

Is Obalon Therapeutics, Inc. (OBLN) Going to Burn These Hedge Funds?

No summary available.

Insider Monkey | June 14, 2021

DGAP-News: ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger

DGAP-News: ReShape Lifesciences Inc. / Key word(s): Merger ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger 08.06.2021 / 13:30 The issuer is solely responsible for the content of this announcement. ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending

Wallstreet:Online | June 8, 2021

ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger

SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc.

Yahoo | June 8, 2021

ReShape Lifesciences Inc., US67424L2097

Reminder: Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences Inc

Ad Hoc News | May 24, 2021

Read More 'OBLN' Stories Here

OBLN Price Returns

1-mo N/A
3-mo -63.43%
6-mo -77.46%
1-year 39.33%
3-year -94.53%
5-year N/A
YTD -32.22%
2020 -21.05%
2019 -90.82%
2018 -68.68%
2017 -25.31%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8551 seconds.